JP2024502034A5 - - Google Patents

Info

Publication number
JP2024502034A5
JP2024502034A5 JP2023539975A JP2023539975A JP2024502034A5 JP 2024502034 A5 JP2024502034 A5 JP 2024502034A5 JP 2023539975 A JP2023539975 A JP 2023539975A JP 2023539975 A JP2023539975 A JP 2023539975A JP 2024502034 A5 JP2024502034 A5 JP 2024502034A5
Authority
JP
Japan
Prior art keywords
cell
nucleic acid
cells
seq
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023539975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502034A (ja
Filing date
Publication date
Priority claimed from DE102021100038.6A external-priority patent/DE102021100038A1/de
Application filed filed Critical
Priority claimed from PCT/US2021/065367 external-priority patent/WO2022147029A2/en
Publication of JP2024502034A publication Critical patent/JP2024502034A/ja
Publication of JP2024502034A5 publication Critical patent/JP2024502034A5/ja
Pending legal-status Critical Current

Links

JP2023539975A 2020-12-31 2021-12-28 Cd8ポリペプチド、組成物、及びそれらの使用方法 Pending JP2024502034A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063132824P 2020-12-31 2020-12-31
US63/132,824 2020-12-31
DE102021100038.6 2021-01-04
DE102021100038.6A DE102021100038A1 (de) 2020-12-31 2021-01-04 Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
US202163247775P 2021-09-23 2021-09-23
US63/247,775 2021-09-23
PCT/US2021/065367 WO2022147029A2 (en) 2020-12-31 2021-12-28 Cd8 polypeptides, compositions, and methods of using thereof

Publications (2)

Publication Number Publication Date
JP2024502034A JP2024502034A (ja) 2024-01-17
JP2024502034A5 true JP2024502034A5 (https=) 2024-12-24

Family

ID=80445995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023539975A Pending JP2024502034A (ja) 2020-12-31 2021-12-28 Cd8ポリペプチド、組成物、及びそれらの使用方法

Country Status (14)

Country Link
US (1) US20250146019A1 (https=)
EP (1) EP4271481A2 (https=)
JP (1) JP2024502034A (https=)
KR (1) KR20230135589A (https=)
AU (1) AU2021411495A1 (https=)
CA (1) CA3203118A1 (https=)
CL (1) CL2023001939A1 (https=)
CO (1) CO2023008645A2 (https=)
CR (1) CR20230295A (https=)
IL (1) IL304157A (https=)
MX (1) MX2023007817A (https=)
PE (1) PE20250846A1 (https=)
TW (1) TW202241938A (https=)
WO (1) WO2022147029A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116715750B (zh) * 2023-03-14 2024-04-12 新景智源生物科技(苏州)有限公司 特异性识别prame抗原的tcr及其与cd8共表达来重定向cd4 t细胞
WO2025096649A1 (en) * 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0633943A4 (en) 1992-04-03 1997-05-02 Alexander T Young GENTHERAPY USING TARGETED VIRAL VECTORS.
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
MY189596A (en) 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US10335471B2 (en) 2015-08-28 2019-07-02 Immatics Biotechnologies Gmbh Method for treating cancer with activated T cells
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
HK1258444A1 (zh) 2015-10-09 2019-11-15 Immatics Biotechnologies Gmbh 抗wt1/hla特异性抗体
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604492D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
NZ746387A (en) 2016-03-16 2022-08-26 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
CN116731156A (zh) 2016-03-16 2023-09-12 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的转染t细胞和t细胞受体
ZA201900664B (en) 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
DE102016115246C5 (de) 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
CN109996868A (zh) * 2016-09-23 2019-07-09 弗雷德哈钦森癌症研究中心 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
EP3300863B1 (en) 2016-09-28 2020-06-17 Braun GmbH Electric shaver
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR20240007775A (ko) 2016-12-08 2024-01-16 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102016123847B3 (de) 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
WO2018189148A1 (en) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
DE102017114737A1 (de) 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
DE102017212608B4 (de) 2017-07-21 2023-11-16 Ford Global Technologies, Llc Radnaben-Einheit mit Wärmedämmbeschichtung zur Reduzierung der thermischen Belastung eines Radlagers
KR20250052472A (ko) 2017-11-06 2025-04-18 이매틱스 바이오테크놀로지스 게엠베하 신규 조작된 t 세포 수용체 및 이를 사용하는 면역 요법
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
DE102018100967B4 (de) 2018-01-17 2019-08-14 Immatics US, Inc. Verfahren zur feststellung der wirksamkeit von viralen vektoren
BR112020016176A2 (pt) 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
CA3097396A1 (en) * 2018-04-19 2019-10-24 Baylor College Of Medicine Reprogramming cd4 t cells into cytotoxic cd8 cells by forced expression of cd8ab and class 1 restricted t cell receptors
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
WO2020185796A1 (en) * 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
WO2020243134A1 (en) * 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
US12011459B2 (en) 2019-06-06 2024-06-18 Immatics US, Inc. Methods for manufacturing T cells by direct sorting and compositions thereof
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren

Similar Documents

Publication Publication Date Title
JP2024502034A5 (https=)
RU2018136607A (ru) Способы и составы для производства лимфоцитов и их регулируемого увеличения
Mitchell et al. Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells
Hashimoto et al. Cytokine-mediated regulation of CD8 T-cell responses during acute and chronic viral infection
Cui et al. Generation of effector CD8+ T cells and their conversion to memory T cells
Wiesel et al. Type I IFN substitutes for T cell help during viral infections
Tovey et al. Adjuvant activity of cytokines
Cortes et al. Interleukin-10 in non-Hodgkin's lymphoma
JP2022534716A5 (https=)
US10286066B2 (en) Artificial antigen presenting cells and uses thereof
US8119772B2 (en) MART-1 T cell receptors
Fadel et al. Cellular immune responses in neonates
Mooij et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates
Minty et al. The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes
JP2015504071A5 (https=)
de Waal Malefyt Interleukin-10
KR20060030041A (ko) IgE 시그날 펩티드 및/또는 IL-15를 암호화하는 핵산서열 및 이를 포함하는 조성물 및 이를 사용하는 방법
CN110075275B (zh) IL-36β的应用
KR20250029152A (ko) 재조합 종양 용해 바이러스 및 이의 응용
JP2024073653A (ja) 遺伝子改変リンパ球の製造方法
JP2021519069A5 (https=)
Ahmad et al. Studies on the production of IL-15 in HIV-infected/AIDS patients
JP2023554674A5 (https=)
US20110195047A1 (en) Oncostatin m as promoter of immunostimulatory activity of human epithelial cells
Raz et al. Deviation of the allergic IgE to an IgG response by gene immunotherapy